Connect with us

Featured

Weed Delivery Is En Route

Daniel Chase

Published

on

stock_price_weed

Back in the day, though this anecdote isn’t necessarily a firsthand account, marijuana enthusiasts would need to go through less-than legal channels to purchase cannabis flower. Typically, people developed relationships with these “business folk,” and would contact them whenever they needed to re-up their inventory. Several years later, and, in most states across the country, there are just as many dispensaries as there are coffee shops and gas stations.

The fact of the matter is that society just doesn’t fear cannabis like they used to, especially after the medical community released information indicating that medicinal cannabis has the potential to be an incredible alternative treatment option. Whereas the question used to be where one could purchase cannabis from, it has now become “how soon can I get pot delivered to my apartment.” 

Special Delivery! On-Demand Tech Companies Hit Billion-Dollar Valuations; Here’s How Investors Can Capitalize In The Market

Yes, in the advent of the delivery app market, companies have sought to include, in their delivery offerings, the ability for consumers to order cannabis and cannabis-related products like tinctures, edibles, and CBD products. When California legalized the recreational use of cannabis in 2018, the industry exploded with excitement. Initially, however, weed delivery companies were still restricted to operating within certain areas of the state. In Northern California, where more than a couple of weed connoisseur reside, many cities refused to allow their citizens to have weed delivered. According to the Sacramento Bee, “residents in about 40% of the state have to drive 60 or more miles” to buy legal weed

While the United States tries to figure out how to operate a cannabis-friendly nation, cannabis companies in Canada are working to increase access to residents across the country. Aside from weed delivery being convenient for people who don’t feel like driving to a dispensary, the ease of access is crucial for medical marijuana patients who truly are incapable of leaving their homes.

ParcelPal Technology Inc (PKG) (PT0.F) (PTNYF) is a delivery tech company which, after rising to the top of the industry because of their on-demand platform, has taken the steps necessary to make sure their on-demand marketplace caters to the needs of all consumers. The Company’s platform has been lauded for its ease of use, and for the fact that, one an order is placed, a ParcelPal courier will deliver a customer’s order in less than an hour. In full recognition of the growing issues related to “pot deserts” across Canada, the Company last week announced that it has signed a cannabis distribution agreement with Kiaro, a Vancouver-based cannabis retailer. 

Per the details of ParcelPal Technology Inc (PKG) (PT0.F) (PTNYF) previously announced cannabis strategy from September 2018, the Company has completed an additional cannabis distribution agreement with Kiaro for the delivery of cannabis products through Kiaro’s physical and digital retail channels. Their distribution initiative will allow for the joint development of an optimal roadmap for the distribution of adult use cannabis, ultimately creating the ‘Amazon Effect’ within the cannabis industry.

Following the announcement of the distribution agreement, Kelly Abbot, Chief Executive Officer of ParcelPal Technology Inc (PKG) (PT0.F) (PTNYF), said, “we are extremely excited to sign a distribution agreement with Kiaro and we will immediately begin planning and executing for all last mile operations. Our objective is to become the Uber of cannabis in Canada and this takes us one step closer to our goal. Cannabis delivery is expensive and often through antiquated courier services – with consumers waiting over a week to receive their items. With ParcelPal, customers will receive their cannabis products safely within an hour. Our technology enables seamless integration with any cannabis retail outlet or eCommerce platform.”

Midam Ventures has been compensated $75,000 per month by a ParcelPal Technology, Inc. for a period beginning September 1, 2018 and ending February 1, 2019 to publicly disseminate information about (PTNYF/PKG) to publicly disseminate information about (PTNYF/PKG).  Midam Ventures has been compensated $100,000 by Parcel Pal and has extended coverage to April 1, 2019. We may buy or sell additional shares of (PTNYF/PKG) in the open market at any time, including before, during or after the Website and Information, provide public dissemination of favorable Information. We own zero shares. Please click here for full disclaimer.

Continue Reading
Click to comment

Biotechnology

2 Biotech Stocks Turning Heads After Key Developments This Quarter

Joe Samuel

Published

on

biotech stocks to watch today

There are very few sectors in the stock market that have consistently produced winning trades. You might be able to count such sectors on one hand. Biotech is certainly among those sectors due to the emergence of highly innovative companies. These firms tend to create new avenues of creation to address unmet medical needs.

There are plenty of promising companies in the sector but it is necessary for an investor to do research thoroughly. It makes finding the best biotech stocks a bit easier. Though no one’s guaranteed a win, sifting out bad stocks is the key. One must watch the market closely to come across promising biotech stocks. Here is a look at two biotech stocks that are worth watching.

Biotech Stocks To Watch: Moleculin Biotech (MBRX)

The first biotech stock to consider is that of Moleculin Biotech Inc (NASDAQ:MBRX), which made some gains on Wednesday on the back of positive interim results for one of its products. The company, which is involved in manufacturing medicines meant for extremely resistant tumors, released data with regards to its acute myeloid leukaemia medicine annamycin.

top biotech stocks to buy

Moleculin revealed highly positive interim data from the Phase ½ clinical study of the medicine and naturally, it has resulted in a lot of excitement in the market with regards to the stock. The stock rose by as much as 2% on the back of the news in yesterday’s trading session. It is one of the key biotech stocks to keep an eye on over the coming days.

Biotech Stocks To Watch: Eyepoint Pharmaceuticals (EYPT)

The other biotech stock that has recorded impressive gains on the market today is the Eyepoint Pharmaceuticals Inc (NASDAQ:EYPT) stock. On Wednesday, the company announced an important deal with regard to dexamethasone intraocular suspension 9% (DEXYCU). Eyepoint announced that it has managed to reach an agreement with one of the biggest players in the U.S. integrated delivery systems.

[Read More] 3 Pharma Stocks To Watch In December 2019

The deal is for two years and the other party is going to offer DEXYCU in its aforesaid systems. It is a major boost for Eyepoint and it has resulted in 5% to close at $1.54 in Wednesday’s trading session.

best biotech stocks to watch today

Continue Reading

Featured

Stock Price Newsletter – December 6, 2019

Joe Samuel

Published

on

stock price newsletter

2 Biotech Stocks to Watch As The Sector Hits New High

The biotech sector has thrown plenty of winners over the course of the last decade or so and if experts are to be believed then it is going to continued to do so for the foreseeable future. Great advancements are being made in the biotech industry and many companies are working on a highly advanced product.

Continue Reading


Is It Time To Buy Or Sell Netflix; Streaming Wars Heat Up

The streaming wars have commenced this month with the launch of Disney Plus and Apple TV+. Many more services are going to be launched over the coming months and the sole purpose of these services is to topple the biggest name in the streaming services, Netflix Inc (NASDAQ:NFLX). The streaming giant has had a hard time this year, due to disappointing subscriber growth.

Click To Read More


Is ROKU Stock a Buy Or Hold on Disney, Apple & Streaming TV Growth?

The stock suffered a slump following its Q3 2019 financial results but since then it has regained much of the losses. While it is true that the losses widened from the year-ago period, experts believe that Roku is a stock that could have long term growth potential.

See For Yourself

Continue Reading

Biotechnology

2 Biotech Stocks to Watch As The Sector Hits New High

Joe Samuel

Published

on

best biotechnology stocks to buy sell

The biotech sector has thrown plenty of winners over the course of the last decade or so and if experts are to be believed then it is going to continued to do so for the foreseeable future. Great advancements are being made in the biotech industry and many companies are working on a highly advanced product.

In such a situation, it is imperative for an intelligent investor to look for companies worth investing in. One should watch the latest developments in the sector and track specific companies closely. Here is a look at two biotech stocks that are worth watching.

Neoleukin Therapeutics

top biotech stocks to watch list

The first biotech stock to watch is that of Neoleukin Therapeutics Inc (NLTX), which has managed to gain significantly over the past two weeks. On November 13, the company released its third-quarter results and since then it has rocketed by as much as 75%. The Canadian company made a loss of $59.1 million in the quarter, which worked out to $2.26 per share.

The company is a biopharmaceutical company that is involved in immunotherapies using de novo protein design technology. The company’s lead product candidate is NL-201, which is an amalgamation of both IL-2 and IL-15 and helps in removing alpha receptor binding.

Verastem

healthcare stocks to buy now

The other biotech stock that is worth watching is Verastem Inc (NASDAQ:VSTM). It made significant gains over the past week. On Monday, the company announced that it has submitted a Marketing Authorization Application for its product COPIKTRA to the European Medicines Agency.

COPIKTRA is a phosphoinositide 3-kinase. It’s meant for patients suffering from refractory chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) and relapsed or refractory follicular lymphoma (FL).

The company is seeking approval for the same in the European market. Verastem stated that it has seen significant improvement in patients who used the product. The stock rocketed by as much as 60% after the news broke and remains one of the stocks to watch this week.

Continue Reading

Join Our Newsletter

Get stock alerts, news & trending stock alerts straight to your inbox!


Privacy Policy

We keep all user information pricate & promise to never spam.*

Stock Price Free Text List

Search Stock Price (StockPrice.com)




Trending

Subscribe Now & Begin Receiving Free Stocks News, Articles, Trade Alerts & MORE, all 100% FREE!

We are your #1 source for all things Stock Market & Finance, Subscribe Below!

Privacy Policy: We will NEVER share, sell, barter, etc. any of our subscribers information for any reason ever! By subscribing you agree we can send you via email our free e-newsletter on stock market & finance related, articles, news and trade alerts. Further questions please contact privacy@stockprice.com